

# Potassium channel antagonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/P1D68D0C36E4EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: P1D68D0C36E4EN

## Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Potassium channel antagonists - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Potassium channel antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Potassium channel antagonists Understanding

#### Potassium channel antagonists: Overview

Potassium channel blockers are agents which interfere with conduction through potassium channels. Potassium is the chief ion in the repolarization. At the end of depolarization, potassium efflux occurs following the opening of the potassium channels. This group of drugs binds to the channel which is responsible for the potassium movement and blocks it. Once the blocking has happened, the refractory period increases.

Function – Potassium-channel blockers comprise the Class III antiarrhythmic

compounds according to the Vaughan-Williams classification scheme. These drugs bind to and block the potassium channels that are responsible for phase 3 repolarization. Therefore, blocking these channels slows (delays) repolarization, which leads to an increase in action potential duration and an increase in the effective refractory period (ERP).

Potassium channel antagonists – Potassium Channel antagonist act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of Action potentials. They are used as Anti-Arrhythmia agents and Vasodilator agents.

### Potassium channel antagonists Emerging Drugs Chapters

This segment of the Potassium channel antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### Potassium channel antagonists Emerging Drugs

#### Amifampridine: BioMarin

Amifampridine (Firdapse) is an orally administered potassium channel antagonist and acetylcholine release stimulant that has been developed by BioMarin. It is being studied in Phase III clinical trials for Myasthenia gravis. The drug has also received orphan drug designation for Myasthenia gravis, Lambert-Eaton myasthenic syndrome; Congenital myasthenic syndromes.

#### Sleep apnoea therapeutic: Bayer

Sleep apnoea therapeutic is a potassium channel antagonists, currently being studied in Phase II stage of development for the treatment of patients with Sleep apnoea syndrome.

Further product details are provided in the report.....

## Potassium channel antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Potassium channel antagonists drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players working on Potassium channel antagonists

There are approx. 10+ key companies which are developing the Potassium channel antagonists. The companies which have their Potassium channel antagonists drug candidates in the most advanced stage, i.e. Phase III include, BioMarin.

### Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III )

Mid-stage products (Phase II )

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Potassium channel antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Potassium channel antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Potassium channel antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Potassium channel antagonists drugs.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Potassium channel antagonists R&D. The therapies under development are focused on novel approaches for Potassium channel antagonists.

## Potassium channel antagonists Report Insights

Potassium channel antagonists Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Potassium channel antagonists Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

## Current Scenario and Emerging Therapies:

How many companies are developing Potassium channel antagonists drugs?

How many Potassium channel antagonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Potassium channel antagonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Potassium channel antagonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Potassium channel antagonists and their status?

What are the key designations that have been granted to the emerging drugs?

## Contents

- Introduction
- Executive Summary
- Potassium channel antagonists: Overview
  - Structure
  - Mechanism of Action
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Potassium channel antagonists – DelveInsight's Analytical Perspective
- In-depth Commercial Assessment
  - Potassium channel antagonists companies' collaborations, Licensing, Acquisition -Deal Value Trends
- Potassium channel antagonists Collaboration Deals
  - Company-Company Collaborations (Licensing / Partnering) Analysis
  - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
  - Comparative Analysis
- Amifampridine: BioMarin
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
  - Comparative Analysis
- Sleep apnoea therapeutic: Bayer
  - Product Description
  - Research and Development
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products
  - Comparative Analysis
- Research programme Kv1.3 potassium channel inhibitors: 4SC

Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report.....  
Inactive Products  
Comparative Analysis  
Potassium channel antagonists Key Companies  
Potassium channel antagonists Key Products  
Potassium channel antagonists- Unmet Needs  
Potassium channel antagonists- Market Drivers and Barriers  
Potassium channel antagonists- Future Perspectives and Conclusion  
Potassium channel antagonists Analyst Views  
Potassium channel antagonists Key Companies  
Appendix



## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Potassium channel antagonists

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Potassium channel antagonists

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Potassium channel antagonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/P1D68D0C36E4EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P1D68D0C36E4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970